|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
CD16/CD66b detected 16 (25.8%) additional patients over CD55/CD59 (P<0.05) and was more sensitive in detecting the PNH clone with higher negative predictive value.
|
29355143 |
2017 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutation of conserved cysteines in proteins of the Ly6 family cause human disease-chylomicronemia in the case of glycosylphosphatidylinositol-anchored HDL binding protein 1 (GPIHBP1) and paroxysmal nocturnal hemoglobinuria in the case of CD59.
|
28476858 |
2017 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
CD59 loss of function is also one of the major thrombophilic mechanisms in patients with paroxysmal nocturnal hemoglobinuria.
|
28622911 |
2017 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Early-onset chronic axonal neuropathy, strokes, and hemolysis: inherited CD59 deficiency.
|
25716358 |
2015 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this review we describe differences and similarities in the pathogenesis and clinical manifestations of PNH and primary CD59 Cys89Tyr mutation with the aim of tracking the contribution of CD59 deficiency to the pathophysiology and perhaps deepening our understanding of both diseases.
|
25818314 |
2015 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal nonneoplastic hematopoietic stem cell disease characterized by an acquired mutation of the PIG-A gene with reduction or absence of CD55 and CD59.
|
25688459 |
2015 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH manifestations.
|
25237200 |
2014 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CD59 deficiency is a common finding in RBCs and WBCs in patients with chronic hemolysis suffering from paroxysmal nocturnal hemoglobinuria in which the acquired mutation in the PIGA gene leads to membrane loss of glycosylphosphatidylinositol-anchored membrane proteins, including CD59.
|
23149847 |
2013 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PNH is due to a somatic, acquired mutation in the X-linked phosphatidylinositol glycan class A (PIG-A) gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 and CD59.
|
23402025 |
2013 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
Loss of CD55 and CD59 on erythrocytes causes complement-mediated lysis in paroxysmal nocturnal hemoglobinuria (PNH), a disease that manifests after clonal expansion of hematopoietic cells with somatic PIGA mutations.
|
22305531 |
2012 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peripheral blood from 489 recently diagnosed patients with aplastic anaemia (AA) and 316 with refractory anaemia (RA) of myelodysplastic syndrome was evaluated to characterize CD55(-)CD59(-) [paroxysmal nocturnal haemoglobinuria (PNH)]-type blood cells associated with bone marrow (BM) failure.
|
19656154 |
2009 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by absence of CD55 and CD59 from the surface of affected cells.
|
18158579 |
2008 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH.
|
17989688 |
2007 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To clarify some characteristics of phosphatidylinositol glycan-class A gene (PIG-A) mutations in aplastic anemia (AA) and myelodysplastic syndrome (MDS) patients compared with those in paroxysmal nocturnal hemoglobinuria (PNH) patients, we investigated PIG-A mutations in CD59- granulocytes and CD48- monocytes from seven AA, eight MDS, and 11 PNH Japanese patients.
|
16467865 |
2006 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic disorder caused by PIGA mutations that lead to a loss of all glycosylphospatidylinositol (GPI)-anchored proteins including, CD55 and CD59.
|
15160958 |
2004 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
Complement-mediated hemolysis in PNH is explained by the deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59 on erythrocyte surfaces.
|
14972783 |
2002 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Unlike PNH cells, 6-TG-resistant cells expressed CD59, indicating that the HPRT mutations did not occur in PNH clones.
|
11756148 |
2002 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
To define the phosphatidylinositol glycan-class A (PIG-A) gene abnormality in precursor cells and the changes of expression of glycosylphosphatidylinositol-anchored protein and contribution of paroxysmal nocturnal hemoglobinuria (PNH) clones with PIG-A gene abnormalities among various cell lineages during differentiation and maturation, we investigated CD59 expression on bone marrow CD34(+) cells and peripheral granulocytes from 3 patients with PNH and the PIG-A gene abnormalities in the CD59(-), CD59(+/-), and CD59(+) populations by nucleotide sequence analyses.
|
12411324 |
2002 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
The degree of reticulocytosis correlated well with the proportion of CD59- (PNH) reticulocytes.
|
11372757 |
2001 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
To assess the hematopoietic defect involved in PNH, CD34+ CD59+ (normal phenotype hematopoietic stem/progenitor) and CD34+ CD59- (PNH phenotype) cells from PNH patients (n = 16) and CD34+ CD59+ cells from healthy volunteers (n = 10) were sorted as single cells into 96-well flat-bottom culture plates containing culture medium supplemented with stem cell factor, interleukin (IL)-3, erythropoietin, granulocyte-macrophage-colony-stimulating factor (GM-CSF), G-CSF, IL-6, thrombopoietin, and Flt-3 ligand.
|
11530804 |
2001 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Using CD59-based immunocytometry, the patterns of CD59 expression were shown to be conserved in the circulating erythroid cells (reticulocytes and mature erythrocytes) in all 29 patients with PNH.
|
10914934 |
2000 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that CD59(-)CD34(+) cells from PNH patients proliferated to levels approaching those of normal cells, but that CD59(+)CD34(+) cells from the patients gave rise to 20- to 140-fold fewer cells.
|
10974022 |
2000 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
When placed in serum-free medium, granulocytes and affected CD34(+) (CD59(-)) cells from PNH patients survived longer than their normal counterparts.
|
9238050 |
1997 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
CD34+ CD59+ and CD34+ CD59-cells from PNH/AA patients showed similarly impaired primary and secondary clonogeneic efficiency.
|
9028939 |
1997 |
|
Paroxysmal nocturnal hemoglobinuria
|
0.500 |
Biomarker
|
disease |
BEFREE |
All metaphases in CD59-deficient bone marrow mononuclear cells had the translocation, whereas none of the CD59-deficient cells had it, indicating that the PNH clone coincided with a cell population bearing the chromosomal aberration.
|
8619404 |
1996 |